FDA Approved: BOSULIF — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)

View source ↗

Summary

FDA approved a supplemental application for BOSULIF (bosutinib) filed by Pfizer, resulting in updated labeling for the drug.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• BOSULIF (bosutinib)

Snippet

SUPPL AP for BOSULIF (BOSUTINIB)